inhibitors

Egbert Smit EGBERT SMIT, Free University of Amsterdam There are a number of promising new molecular targets for lung cancer chemotherapy which were discussed at the Turin congress by Egbert Smit. He t

Silvia Novello SILVIA NOVELLO, University of Turin Future improvements in drug treatment of lung cancer may be made by inhibiting more than one tyrosine kinase simultaneously. So said Silvia Novello w

Jack Cuzick JACK CUZICK, Wolfson Institute of Preventive Medicine, London New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continu

Jean-Yves Douillard Gordon McVie REFERENCE: Abstracts: 6507 & 2LB, ECCO 14, The European Cancer Conference, Barcelona, 23 Р27 September 2007 JEAN-YVES DOUILLARD, Centre Ren̩ Gauducheau, N

Anthony Fung REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida ANTHONY FUNG, University of British Columbia, Vanc

Pierre Laurent-Puig Bill Hait REFERENCE: ABSTRACT: 5671, American Association for Cancer Research, April 14-18, 2007, Los Angeles PIERRE LAURENT-PUIG, Hôpital Européen Georges Pompidou, Paris COMMEN

Paul Fisher REFERENCE: Meet the Professor Session, AACR 2007, Los Angeles PAUL FISHER, Columbia University, New York Patients with cancer could soon be treated with adenoviruses capable of infecting b

RODGER MACARTHUR, Wayne State University, Detroit REFERENCE: Lancet 2006; 368: 2125-35 A three-class HIV antiretroviral therapy is not necessary, according to data published in the Lancet. The FIRST s